RT Journal Article
SR Electronic
T1 BNT162b2 COVID-19 mRNA vaccine elicits a rapid and synchronized antibody response in blood and milk of breastfeeding women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.06.21252603
DO 10.1101/2021.03.06.21252603
A1 Friedman, Michal Rosenberg
A1 Kigel, Aya
A1 Bahar, Yael
A1 Yogev, Yariv
A1 Dror, Yael
A1 Lubetzky, Ronit
A1 Many, Ariel
A1 Wine, Yariv
YR 2021
UL http://medrxiv.org/content/early/2021/03/08/2021.03.06.21252603.abstract
AB We describe the dynamics of the vaccine-specific antibody response in the breastmilk and serum in a prospective cohort of ten lactating women who received two doses of the Pfizer-BioNTech BNT162b2 COVID-19 mRNA vaccine. The antibody response was rapid and highly synchronized between breastmilk and serum, reaching stabilization 14 days after the second dose. The predominant serum antibody was IgG. The response in the breastmilk included both IgG and IgA with neutralizing capacity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Israeli Ministry of Health (MOH) grant #3-0000-17162)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sample collection was performed under the following ethical approvals: 1/ Institutional review board (IRB) approvals number 0002269-4 and 0002757-1 given at Tel Aviv University. Chair of IRB committee Prof. Meir Lahav, Faculty Medicine, Tel Aviv University. 2/ Ethical approval number 1088-20-TLV given at Tel Aviv Sourasky medical center. Prof. Shmuel Kivity, Chairman, Institutional Review Board (IRB) / Ethics (Helsinki) Committee,Tel Aviv Sourasky medical center and under approval by the director of Tel Aviv Sourasky medical center, Prof. Ronni Gamzu. All participants provided informed consent for the use of their data and clinical samples for the purposes of the present study. Study participant's data includes less than three indirect identifiers throughout the manuscript in compliance with ethical guidelines. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request due to privacy or other restrictions